As targeted therapies are becoming more common on the market and prescribed by physicians, it is necessary to develop strategies to support patients with this new treatment modality. Auto-injectors require patients to administer their own medication. While they can be time and cost-effective, less than 50% of patients continue to adhere to their treatment after six months. A study conducted in 2019 found that medication non-adherence costs are estimated to be between $100 to $290 billion in the United States and approximately 1.25 billion € in Europe annually. In this article, we break down the self-administration process into three phases, each with specific end goals.
"*" indicates required fields
* to process your contact request. If you do not fill them in, your request cannot be processed. To find out more about the use of your personal data and how to exercise your rights, please consult the Privacy Policy
